secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apimeds Pharmaceuticals US, Inc. (APUS)
CIK:        0001894525
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0001213900-25-042122
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apimeds Pharmaceuticals US completes $13.5M IPO; starts trading on NYSE American
--------------------------------------------------------------------------------

- IPO of 3,375,000 shares at $4.00/share; gross proceeds $13.5M.
- Proceeds to fund Phase III knee osteoarthritis trial, MS study, manufacturing, working capital.
- Convertible notes of $772,545 converted into 297,133 shares at $2.60/share.
- Underwriters granted 45-day option for 506,250 additional shares and warrants for 168,750 shares.
- Trading began May 9, 2025 on NYSE American under symbol APUS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894525/000121390025042122/0001213900-25-042122-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894525/000121390025042122/ea0241711-8k_apimeds.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-042122

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer